Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is gen ...
Ionis Pharmaceuticals, Inc. (the "Company") today reported financial results and provided key updates for the third quarter ended September 30, 2025. "The third quarter was a watershed moment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback